-transparent.png){kind=logo}
Inhibitory effect of a serine protease inhibitor, FOY-305 on the invasion and metastasis of human pancreatic cancers. 1997
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
KANAZAWA UNIV,SCH MED,DEPT SURG,KANAZAWA,ISHIKAWA 920,JAPAN. KANAZAWA UNIV,SCH MED,DEPT ANAT,KANAZAWA,ISHIKAWA 920,JAPAN. KANAZAWA UNIV,SCH MED,DEPT PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN. TOTTORI UNIV,FAC MED,DEPT PATHOL,YONAGO,TOTTORI 683,JAPAN.
We examined the inhibitory effect of a serine protease inhibitor, FOY-305, on the invasion and metastasis of human pancreatic cancers. The in vitro matrigel invasion assay showed that the invasiveness of Capan-1 human pancreatic cancer cells was inhibited by FOY-305 treatment in a dose-dependent manner at concentrations greater than 100 nM. Intrasplenic injection of Capan-1 cells in nude mice resulted in frequent metastases to liver, however, its incidence was significantly decreased by FOY-305 treatment. These findings suggest that a serine protease inhibitor, FOY-305 can inhibit tumor invasion and metastasis by blocking the serine protease-mediated activation cascade.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
January 2005,
In vivo (Athens, Greece),
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
January 1993,
Anticancer research,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
March 1987,
Hiroshima journal of medical sciences,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
May 1983,
Pharmacological research communications,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
September 1996,
International journal of oncology,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
January 1997,
Oncology reports,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
May 1984,
Klinische Wochenschrift,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
June 1984,
Zeitschrift fur Gastroenterologie,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
May 1997,
International journal of oncology,
T Ohta, and
F Futagami, and
H Tajima, and
H Kitagawa, and
M Kayahara, and
T Nagakawa, and
K Miwa, and
M Yamamoto, and
S Iseki, and
Y Nakanuma, and
T Terada
February 2015,
Oncology reports,
